echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Big potential! "Concentrated firepower" against liver cancer in the "concentrated firepower" combination of TheOpdivo and Yervoy combination of Time Squibb

    Big potential! "Concentrated firepower" against liver cancer in the "concentrated firepower" combination of TheOpdivo and Yervoy combination of Time Squibb

    • Last Update: 2020-06-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    CheckMate-040 is an ongoing open label, multi-queue study that is evaluating the efficacy and safety of Opdivo or Opdivo-based combination therapies in advanced HCC patients with or without viral hepatitis, who are treated with sorafenib (sorafenib) for initial treatment, intolerance, or progression during treatment with the drugstudy, the OY queue was an exploratory queue to assess the safety and effectiveness of three different combinations of administration: (1) Group A: Acceptance of The Opdivo 1mg/kg and Yervoy 3mg/kg combination (O1Y3) treated once every 3 weeks (Q3W) for 4 cycles, followed by every 2 weeks (Q2W) Opdivo 240mg; Group B: Receive Opdivo 3mg/kg and Yervoy 1mg/kg combination (O3Y1) Q3W treatment for 4 cycles, followed by Opdivo 240mg (Q2W) ;(3) C: Receive Opdivo 3mg/kg Q2W and Yervoy 1mg/kg once every 6 weeks (Q6W)follow-up for a minimum of 28 months, the objective mitigation rate (ORR) assessed by the Independent Center for Blindness (BICR) was 31%, and the median mitigation duration (DoR) at data cut-off was 17.5 months (95% CI: 11.1-N/A)Meaningful remission was observed in all three treatment groups, with group A patients experiencing the longest median OS in the queue at 22.8 months (95% CI: 9.4-N/A) and 30 months with an OS rate of 44% (95% CI: 29.5-57)the use of solid tumor efficacy evaluation criteria 1.1 (RECIST v1.1) evaluation, the disease control rate (DCR) in the three groups were 54%, 43%, 49%Throughout the queue, 5% of patients reached full remission and 26% achieved partial remission, which was not related to the baseline tumor PD-L1 stateIn the study, the OY combination showed acceptable safety, and none of the treatment groups produced new safety signalsThomas Yau, M.D., clinical associate professor of medicine at the University of Hong Kong,, said: "HCC remains an important medical need that has not yet been met because it is usually diagnosed at a later stage and treatment options are limitedThe results announced at the meeting showed that the addition of Yervoy to the Opdivo protocol could trigger promising clinical remission in patients with advanced HCC, reaffirming the important potential impact of the joint study"Opdivo was approved by the FDA in 2017 as the first immuno-oncology drug to treat this invasive cancer, and has been an important treatment option for patients with advanced HCC," said Ian MWaxman, head of gastrointestinal cancer development at.SPhishimeWe are very encouraged by the efficacy of the Opdivo-Yervoy combination observed in the CheckMate-040 study, and we are grateful to the patients and researchers involved in the studyliver cancer is the fourth most common cause of cancer death in the world, while hepatocellular carcinoma (HCC) is the most common type of liver cancer and the fastest-growing cancer-related cause of death in the United StatesHCC is usually diagnosed at a late stage, effective treatment options are limited, and first-line care standards provide less than 3 months of survival benefits compared to placebosAlthough most HCC cases are caused by HBV or HCV infections, the prevalence of metabolic syndrome and non-alcoholic fatty hepatitis (NASH) is on the rise and is expected to lead to an increase in hCC incidence(Sina Pharma Compilation/new)Reference Source:1.Bristol-Myers Squibb Announces First Presentation of Results for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination In Advanced Advanced oma at ASCO 20192.https://news.bms.com/press-release/asco19/bristol-myers-squibb-announces-first-presentation-results-results-opdivo-nivolumab-plus
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.